Gupta 2002.

Methods	Randomised trial. Method of randomisation not stated. Single centre in New Delhi, India. Total duration of trial 1.5 to 2 years in both study groups. Ethical approval/consents not stated.
Participants	81 participants, 41 people with NCC treated for 6 months in group A, 40 people with NCC treated for a period of 12 months in group B. Diagnostic criteria based on CT Scan findings. Age and sex distribution not stated. Inclusion criteria: all patients with epilepsy and diagnostic CT findings, only patients with a single lesion. Exclusion criteria: suspected tuberculoma and NCC patients treated with albendazole. Follow‐up: 12 months after drug withdrawal.
Interventions	AED treatment for seizure control for 6 months in group A and 12 months in group B. Details of drug used, dosage in either groups not stated.
Outcomes	Seizure recurrence after stoppage of treatment.
Notes	Single outcome studied. Withdrawls and exact number of excluded patients not stated. Choice of AED not mentioned. Dosage, side effects, cost and impact on quality of life not studied.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Method of randomisation not detailed
Allocation concealment (selection bias)	Unclear risk	Exact methodology not detailed in the article
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not mentioned in article, probably not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Method of outcome recording not stated
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Withdrawals, exclusions and reasons (if any) not stated
Selective reporting (reporting bias)	Unclear risk	Protocol not available. Insufficient information to comment on reporting
Other bias	High risk	AED used, formulation and dosage not stated in the article